ngµç×ÓÓÎÏ·

05

¿ÆÑÐÏ£Íû

ngµç×ÓÓÎϷҩѧԺÕÔ´ºË³½ÌÊÚ¿ÎÌâ×éÔÚ¹¹½¨¹¤³Ì»¯¾ÞÊÉϸ°ûÓÃÓÚÈéÏÙ°©¹Ç×ªÒÆÖÎÁÆÁìÓòÈ¡µÃÐÂÏ£Íû

¸å¼þȪԴ£ºÒ©Ñ§Ôº ÔĶÁÁ¿£º

ngµç×ÓÓÎÏ·ÐÂÎÅÍøÑ¶£¨Í¨Ñ¶Ô±»ÆÑ޾꣩Ö×Áö×ªÒÆÊÇÆäÖÂËÀµÄÖ÷ÒªÒòËØ£¬£¬£¬ÆäÖйÇ×ªÒÆÓÈÉõ¡£¡£¡£ÈéÏÙ°©µÄ¹Ç×ªÒÆ·¢²¡Âʸߴï65~80%£¬£¬£¬¼Ì¶øÒýÆðÍç¹ÌÐÔ¹ÇÍ´¡¢¼¹Éñ¾­Õ¥È¡¡¢¸ß¸ÆÑªÖ¢¡¢¹ÇÕÛ¼°¹ÇÈÜÊ´µÈÖÂÃüÐÔ²¢·¢Ö¢£¬£¬£¬ÑÏÖØ½µµÍ»¼ÕßµÄÉúÑÄÖÊÁ¿¡£¡£¡£Òò´Ë£¬£¬£¬ÓÐÓ÷ÀÖÎÈéÏÙ°©¼°ÆäÔ¶¶Ë¹Ç×ªÒÆÊÇÁÙ´²Ö®¼±Ðè¡£¡£¡£

ngµç×ÓÓÎϷҩѧԺÕÔ´ºË³½ÌÊÚ¿ÎÌâ×éºã¾ÃרעÓÚÈéÏÙ°©¹Ç×ªÒÆÖÎÁÆÑо¿£¬£¬£¬¿ËÈÕÔÚȨÍþÆÚ¿¯Nature communicationsÔÓÖ¾ÔÚÏß½ÒÏþÁËÌâΪ¡°Engineered macrophages as near-infrared light activated drug vectors for chemo-photodynamic therapy of primary and bone metastatic breast cancer¡±µÄÑо¿ÂÛÎÄ£¬£¬£¬²¢ÒÑÉêÇë1ÏîÖйú·¢Ã÷רÀû£¨ÉêÇëºÅ£ºCN202110760793.7£©¡£¡£¡£¸ÃÑо¿»ùÓÚÈéÏÙ°©¹Ç×ªÒÆµÄ¼²²¡ÌØÕ÷£¬£¬£¬ÕûºÏ°ÂɳÀû²¬Ç°Ò©¼°¹âÃô»îÐÔ·Ö×ÓµÄÓÅÊÆ£¬£¬£¬¹¹½¨Á˽üºìÍâ¹â¼¤»îÐ͹¤³Ì»¯¾ÞÊÉϸ°û-ǰҩµÝÒ©ÔØÌ壬£¬£¬Ö¼ÔÚʵÏÖ¹â¿ØÊÍÒ©¼°»¯ÁÆ-¹â¶¯Á¦£¨PDT£©ÁªºÏÖÎÁƵÄЧ¹û¡£¡£¡£

¸Ãϸ°ûµÝҩϵͳ¾ßÓÐÔØÒ©Á¿¸ß¡¢Ï¸°û»îÁ¦¸ß¡¢µÝҩЧÂʸ߼°Ò©Îï¿É¿ØÊͷŵÈÌØÕ÷£¬£¬£¬ÓÚÌåÄÚ¿Éͬ²½°ÐÏòµ½Ô­·¢Áö¼°¹Ç×ªÒÆÁöÇøÓò£¨ÈçͼËùʾ£©¡£¡£¡£ÔÚÔ­·¢Ö×Áö²¿Î»¾ÙÐнüºìÍâ¹âÕÕÉ䣬£¬£¬¿É¼¤»î¹âÃô»îÐÔ·Ö×ӵĹ⶯Á¦ÖÎÁÆ£¬£¬£¬ÊµÏÖ£º¢Ù¿É¿Ø´¥·¢²¢¼ÓËÙ°ÂɳÀû²¬´Óϸ°ûÔØÌåÖеÄÊÍ·Å£¬£¬£¬Ê©Õ¹ÆäÓÕµ¼Ï¸°ûÃâÒßÔ­ÐÔéæÃü£¨immunogenic cell death, ICD£©¹¦Ð§£»¢Ú»¯ÁÆÓë¹â¶¯Á¦ÖÎÁƵÄÁªºÏ£¬£¬£¬²»µ«ÏÔÖøÒÖÖÆÔ­·¢Ö×Áö£¬£¬£¬ÇÒÄÜÁªºÏÓÕµ¼ICDµÄ±¬·¢¼¤»îÃâÒßϵͳ£¬£¬£¬Ôö½øÊ÷ͻ״ϸ°û£¨dentritic cells, DCs£©³ÉÊ죬£¬£¬²¢Ôö½øÁöÄÚCD8+Tϸ°ûºÍCD4+Tϸ°ûµÄ½þÈ󣬣¬£¬Í¬Ê±Ìá¸ßѪÇåÖÐIFN-¦ÃºÍTNF-¦ÁµÄˮƽ£¬£¬£¬ÓëPD-L1¿¹ÌåÁªºÏºóÏÔÖøÒÖÖÆÔ­·¢Áö¼°¹Ç×ªÒÆÁö£¬£¬£¬²¢ÏÔÖø»º½âÖ×Áö×ªÒÆµ¼ÖµĹÇÈÜÊ´¡£¡£¡£±ðµÄ£¬£¬£¬¸Ã»¯ÁÆ-¹â¶¯Á¦-ÃâÒßÁªºÏÖÎÁÆÏµÍ³¸³ÓèÁËСÊóºã¾Ã¿¹Ö×ÁöÃâÒßÓ°ÏóЧӦ£¬£¬£¬²¢ÏÔÖøÑÓÉìÁËСÊóµÄÉúÑÄÆÚ£¬£¬£¬ÇÒÉúÎïÏàÈÝÐÔÓÅÒì¡£¡£¡£

¸Ã¹¤³Ì»¯¾ÞÊÉϸ°ûµÝÒ©ÔØÌåµÄÖÎÁÆÄ£Ê½£¬£¬£¬ÎªÈéÏÙ°©Ô­·¢¼°¹Ç×ªÒÆµÄÖÎÁÆÌṩÁËÒ»ÖÖ»¯ÁÆ-¹â¶¯Á¦-ÃâÒßЭͬÖÎÁƵÄÐÂģʽ¡£¡£¡£

Ê×Ò³|ngµç×ÓÓÎÏ·Öйú¼¯ÍŹٷ½ÍøÕ¾

¹¤³Ì»¯¾ÞÊÉϸ°ûµÝÒ©ÔØÌåµÄ×÷ÓûúÖÆÊ¾Òâͼ

ngµç×ÓÓÎϷҩѧԺÕÔ´ºË³½ÌÊÚΪÂÛÎĵÄͨѶ×÷Õߣ¬£¬£¬Ò©Ñ§Ôº»ÆÑ޾격ʿºóΪÂÛÎĵÚÒ»×÷Õß¡£¡£¡£¸ÃÑо¿»ñµÃ¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÓëÖйú²©Ê¿ºó¿ÆÑ§»ù½ðµÄ¾­·ÑÖ§³Ö¡£¡£¡£

ÂÛÎÄÁ´½Ó£ºhttps://doi.org/10.1038/s41467-021-24564-0

¡¾ÍøÕ¾µØÍ¼¡¿